Association of DNA mismatch repair and mutations in BRAF and KRAS with survival after recurrence in stage III colon cancers: A secondary analysis of 2 randomized clinical trials

JAMA Oncology

Volumn 3, Issue 4, 2017, Pages 472-480

  Sinicrope, Frank A ^a,b   Shi, Qian ^a   Allegra, Carmen J ^c   Smyrk, Thomas C ^a   Thibodeau, Stephen N ^a   Goldberg, Richard M ^d   Meyers, Jeffrey P ^a   Pogue Geile, Kay L ^e   Yothers, Greg ^f   Sargent, Daniel J ^a   Alberts, Steven R ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e NSABP Foundation Inc   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; BRAF PROTEIN, HUMAN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; KRAS PROTEIN, HUMAN; PLATINUM COMPLEX; PROTEIN P21; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; CANCER STAGING; COLON TUMOR; CONTROLLED STUDY; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MISMATCH REPAIR; MORTALITY; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL ANALYSIS; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BIOMARKERS, TUMOR; CETUXIMAB; COLONIC NEOPLASMS; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); SURVIVAL ANALYSIS;

EID: 85018560281     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.5469     Document Type: Article

References (37)

1. Shi Q, Andre T, Grothey A, et al. Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database. J Clin Oncol. 2013;31(29):3656-3663.
2. V600E in patients with lymph node-positive colon cancer. Curr Colorectal Cancer Rep. 2014;10(3):346-353.
3. Kawakami H, Zaanan A, Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options Oncol. 2015;16(7):30.
4. Klingbiel D, Saridaki Z, Roth AD, Bosman FT, Delorenzi M, Tejpar S. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. Ann Oncol. 2015;26(1):126-132.
5. Sinicrope FA, Shi Q, Smyrk TC, et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology. 2015;148(1):88-99.
6. Sinicrope FA, Mahoney MR, Yoon HH, et al; Alliance for Clinical Trials in Oncology. Analysis of molecular markers by anatomic tumor site in stage III colon carcinomas from adjuvant chemotherapy Trial NCCTG N0147 (Alliance). Clin Cancer Res. 2015;21(23):5294-5304.
7. Gavin PG, Paik S, Yothers G, Pogue-Geile KL. Colon cancer mutation: prognosis/prediction - response. Clin Cancer Res. 2013;19(5):1301.
8. André T, de Gramont A, Vernerey D, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC Study. J Clin Oncol. 2015;33(35):4176-4187.
9. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117(20):4623-4632.
10. Sinicrope FA, Mahoney MR, Smyrk TC, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013;31(29):3664-3672.
11. Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol. 2010;21(12):2396-2402.
12. Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012;18(3):890-900.
13. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28(3):466-474.
14. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330-337.
15. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38(7):787-793.
16. Yoon HH, Tougeron D, Shi Q, et al; Alliance for Clinical Trials in Oncology. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147). Clin Cancer Res. 2014;20(11):3033-3043.
17. Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29(10):1261-1270.
18. Imamura Y, Morikawa T, Liao X, et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res. 2012;18(17):4753-4763.
19. Taieb J, Tabernero J, Mini E, et al; PETACC-8 Study Investigators. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(8):862-873.
20. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307(13):1383-1393.
21. Allegra CJ, Yothers G, O'Connell MJ, et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol. 2013;31(3):359-364.
22. Popovici V, Budinska E, Bosman FT, Tejpar S, Roth AD, Delorenzi M. Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer. BMC Cancer. 2013;13:439.
23. Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012;18(23):6531-6541.
24. Makuch RW. Adjusted survival curve estimation using covariates. J Chronic Dis. 1982;35(6):437-443.
25. Gail MH, Byar DP. Variance calculations for direct adjusted survival curves, with applications to testing for no treatment effect. Biometrical J. 1986;28(5):587-599.
26. Zhang X, Loberiza FR, Klein JP, Zhang MJ. A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Programs Biomed. 2007;88(2):95-101.
27. Schenfeld D. Residuals for the proportional hazards regresssion model. Biometrika. 1982;69(1):239-241.
28. Wilcox RE, Shi Q, Sinicrope FA, et al. Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) (Alliance Trial N0147). J Clin Oncol. 2015;33(suppl):abstract 3590. http://meetinglibrary.asco.org/content/150501-156. Accessed November 17, 2016.
29. Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009;27(35):5931-5937.
30. Association for Molecular Pathology. ASCP/CAP/AMP/ASCO Evaluation of Molecular Markers for Colorectal Cancer: draft recommendations. http://www.amp.org/committees/clinical-practice/CRCOpenComment.cfm. Accessed November 17, 2016.
31. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350-1356.
32. Venook AP, Niedzwiecki D, Innocenti F, et al. Impact of primary tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34(suppl):abstract 3504. http://meetinglibrary.asco.org/content/161936-176. Accessed November 17, 2016.
33. Missiaglia E, Jacobs B, D'Ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25(10):1995-2001.
34. National Comprehensive Cancer Network. NCCN Biomarkers Compedium. https://www.nccn.org/professionals/biomarkers/content/. Accessed November 17, 2016.
35. Morris VK, Lucas FA, Overman MJ, et al. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol. 2014;25(10):2008-2014.
36. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509-2520.
37. Corcoran RB, Atreya CE, Falchook GS, et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol. 2015;33(34):4023-4031.